公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2013 | Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group | Kim S.J.; CHIUN HSU ; Song Y.-Q.; Tay K.; Hong X.-N.; Cao J.; Kim J.S.; Eom H.S.; Lee J.H.; Zhu J.; Chang K.-M.; Reksodiputro A.H.; Tan D.; Goh Y.T.; Lee J.; Intragumtornchai T.; Chng W.-J.; ANN-LII CHENG ; Lim S.T.; Suh C.; Kwong Y.-L.; Kim W.S. | European Journal of Cancer | 98 | 90 | |
2014 | A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma | Ogura M.; Ando K.; Suzuki T.; Ishizawa K.; Oh S.Y.; Itoh K.; Yamamoto K.; Au W.Y.; HWEI-FANG TIEN ; Matsuno Y.; Terauchi T.; Yamamoto K.; Mori M.; Tanaka Y.; Shimamoto T.; Tobinai K.; Kim W.S. | British Journal of Haematology | 102 | 86 | |
2015 | Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: Pharmacokinetics and recommended phase 2 dose | Venkatakrishnan K.; Kim T.M.; CHIA-CHI LIN ; Thye L.S.; Chng W.J.; Ma B.; Chen M.H.; Zhou X.; Liu H.; Kelly V.; Kim W.S. | Investigational New Drugs | 26 | 27 |